Working… Menu

Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02438410
Recruitment Status : Completed
First Posted : May 8, 2015
Last Update Posted : December 6, 2019
Information provided by (Responsible Party):
Darrell S. Pardi, M.D., Mayo Clinic

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : December 4, 2019
Actual Study Completion Date : December 4, 2019
Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflammatory Bowel Diseases 1995;1:48-63.
Brandse J.F. MWM, de Bruyn J., Wolbink GJ., Lowenberg M., Ponsioen C., van den Brink G.R., D'Haens G.R. Fecal Loss of Infliximab As a Cause of Lack of Response in Severe Inflammatory Bowel Disease. Gastroenterology May 2013;144:S-36.